{
  "guideline": {
    "id": "PA166184527",
    "name": "Annotation of DPWG Guideline for brexpiprazole and CYP2D6",
    "objCls": "Guideline Annotation",
    "source": "DPWG",
    "version": 11,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166184527",
    "relatedChemicals": [
      {
        "id": "PA166160053",
        "name": "brexpiprazole",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166302132",
      "name": "Recommendation Annotation PA166302132",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166160053",
          "name": "brexpiprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103671,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "The gene variation results in a reduction of the exposure to brexpiprazole, but there are no indications supporting a decrease in efficacy."
      ],
      "lookupKey": {
        "CYP2D6": "4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302136",
      "name": "Recommendation Annotation PA166302136",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166160053",
          "name": "brexpiprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103675,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "The gene variation results in a reduction of the exposure to brexpiprazole, but there are no indications supporting a decrease in efficacy."
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302123",
      "name": "Recommendation Annotation PA166302123",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166160053",
          "name": "brexpiprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103662,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "There are indications supporting an increase in the exposure to brexpiprazole, but no indications supporting an increase in side effects in patients with this gene variation."
      ],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302127",
      "name": "Recommendation Annotation PA166302127",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA166160053",
          "name": "brexpiprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103666,
        "html": "<p>The guideline does not provide a recommendation for brexpiprazole in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on brexpiprazole."
      ],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302131",
      "name": "Recommendation Annotation PA166302131",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166160053",
          "name": "brexpiprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103670,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "The gene variation results in a reduction of the exposure to brexpiprazole, but there are no indications supporting a decrease in efficacy."
      ],
      "lookupKey": {
        "CYP2D6": "3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302122",
      "name": "Recommendation Annotation PA166302122",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166160053",
          "name": "brexpiprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103661,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "There are indications supporting an increase in the exposure to brexpiprazole, but no indications supporting an increase in side effects in patients with this gene variation."
      ],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302135",
      "name": "Recommendation Annotation PA166302135",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166160053",
          "name": "brexpiprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103674,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "The gene variation results in a reduction of the exposure to brexpiprazole, but there are no indications supporting a decrease in efficacy."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302126",
      "name": "Recommendation Annotation PA166302126",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA166160053",
          "name": "brexpiprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103665,
        "html": "<p>The guideline does not provide a recommendation for brexpiprazole in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on brexpiprazole."
      ],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302130",
      "name": "Recommendation Annotation PA166302130",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA166160053",
          "name": "brexpiprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103669,
        "html": "<p>The guideline does not provide a recommendation for brexpiprazole in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on brexpiprazole."
      ],
      "lookupKey": {
        "CYP2D6": "2.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302134",
      "name": "Recommendation Annotation PA166302134",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166160053",
          "name": "brexpiprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103673,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "The gene variation results in a reduction of the exposure to brexpiprazole, but there are no indications supporting a decrease in efficacy."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302121",
      "name": "Recommendation Annotation PA166302121",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166160053",
          "name": "brexpiprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103660,
        "html": "<p>Use half of the normal dose.</p>\n"
      },
      "implications": [
        "The risk of side effects is theoretically increased, because the gene variation reduces the metabolism of brexpiprazole."
      ],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302138",
      "name": "Recommendation Annotation PA166302138",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166160053",
          "name": "brexpiprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103677,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "The gene variation results in a reduction of the exposure to brexpiprazole, but there are no indications supporting a decrease in efficacy."
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302125",
      "name": "Recommendation Annotation PA166302125",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166160053",
          "name": "brexpiprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103664,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "There are indications supporting an increase in the exposure to brexpiprazole, but no indications supporting an increase in side effects in patients with this gene variation."
      ],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302129",
      "name": "Recommendation Annotation PA166302129",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA166160053",
          "name": "brexpiprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103668,
        "html": "<p>The guideline does not provide a recommendation for brexpiprazole in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on brexpiprazole."
      ],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302133",
      "name": "Recommendation Annotation PA166302133",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166160053",
          "name": "brexpiprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103672,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "The gene variation results in a reduction of the exposure to brexpiprazole, but there are no indications supporting a decrease in efficacy."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302124",
      "name": "Recommendation Annotation PA166302124",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166160053",
          "name": "brexpiprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103663,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "There are indications supporting an increase in the exposure to brexpiprazole, but no indications supporting an increase in side effects in patients with this gene variation."
      ],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302137",
      "name": "Recommendation Annotation PA166302137",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166160053",
          "name": "brexpiprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103676,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "The gene variation results in a reduction of the exposure to brexpiprazole, but there are no indications supporting a decrease in efficacy."
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302128",
      "name": "Recommendation Annotation PA166302128",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA166160053",
          "name": "brexpiprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103667,
        "html": "<p>The guideline does not provide a recommendation for brexpiprazole in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on brexpiprazole."
      ],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "37002327",
      "title": "Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.",
      "authors": [
        "Beunk Lianne",
        "Nijenhuis Marga",
        "Soree Bianca",
        "de Boer-Veger Nienke J",
        "Buunk Anne-Marie",
        "Guchelaar Henk Jan",
        "Houwink Elisa J F",
        "Risselada Arne",
        "Rongen Gerard A P J M",
        "van Schaik Ron H N",
        "Swen Jesse J",
        "Touw Daan",
        "van Westrhenen Roos",
        "Deneer Vera H M",
        "van der Weide Jan"
      ],
      "journal": "European journal of human genetics : EJHG",
      "year": 2023,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/37002327"
    }
  ],
  "version": "2024-03-08-14-34"
}